Onshore yuan (CNY) closed at 6.7181 per dollar at 16:30 on Sept. 3, up 38 pips from the previous trading day.

美國商務部長盧特尼克：正在考慮半導體關稅。

China’s National Medical Products Administration approved Genzyme Corporation’s Class 1 innovative drug rilzabrutinib tablets (trade name Sailizhi) for adults with persistent or chronic primary immune thrombocytopenia (ITP) who had inadequate response or intolerance to corticosteroids, IVIG or other prior therapies. The approval establishes a new treatment option for this patient population in China.